PureTech Health plc

NASDAQ:PRTC

Biotechnology

Healthcare
$17.38 +2.64%

+$0.45 today

Market cap
$423.09M
Beta
0.79
P/E (TTM)
-0.4
EPS (TTM)
-$45.37
52W Low $14.50High $19.92

Volume 0.01M

Average 0.01M

PRTC Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

PureTech Health plcNASDAQ: PRTC

Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025

Stock-based compensation outflow shrinks to $0

Q4 FY2025 stock-based compensation was $0, compared with $18.2M a year earlier. Over 3 fiscal years it compounded at -17.6% a year.

Context

  • Stock-based compensation amounted to 176.5% of revenue in FY2025, down 296.8 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$8.22M-64.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-64.0%——
3-year CAGR-17.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
8.22M USD
Year-over-year change
-64.0%
4-year CAGR
-12.4%

Stock-Based Compensation vs competitors

How PRTC compares with its peers on the latest reported figures

  • PRTC's FY2025 stock-based compensation of $8.22M is the 9th largest of the 11 companies compared; the peer median is $13.88M.
  • Its year-over-year change of -64.0% is the 10th highest of 11, against a peer median of -6.5%.
  • Stock-based compensation amounts to 176.5% of revenue for PRTC, versus a peer median of 31.8%.
PRTC Competitors Peer median
Stock-Based Compensation for PRTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$36.4M -7.4%+94.0%492.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M -20.0%+6.1%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$27.96M -33.3%+53.3%—
SLDBSolid Biosciences Inc.LTM Mar 2026$18.73M +52.9%+30.9%—
AUTLAutolus Therapeutics plcLTM Mar 2026$15.14M -5.7%+6.3%16.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M +26.4%-48.5%16.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026$12.56M +183.6%+171.6%—
QSIQuantum-Si incorporatedLTM Mar 2026$10.98M +14.3%-1.3%592.7%
PRTCPureTech Health plcFY2025$8.22M -64.0%-17.6%176.5%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$4.71M -8.3%+3.5%31.8%
NGNENeurogene Inc.LTM Mar 2026$3.41M -69.9%+124.6%—
Peer median (excluding PRTC) $13.88M-6.5%+18.6%31.8%

Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(62.71M)(37.07M)(65.7M)27.78M(110M)
Depreciation & Amortization7.29M8.89M4.93M3.57M3.36M
Deferred Income Tax(112.61M)(70.12M)000
Stock-Based Compensation13.95M14.7M4.42M22.85M8.22M
Change in Working Capital861K15.92M17.52M(10.24M)(3.13M)
Accounts Receivables(617K)(7.73M)9.75M629K(236.55K)
Inventory(103K)0000
Accounts Payables8.34M22.03M3.84M(9.7M)(1.03M)
Other Working Capital(6.76M)1.62M3.93M(1.17M)(1.87M)
Other Non-Cash Items(5.05M)(111.12M)(67.09M)(178.34M)16.22M
Operating Cash Flow(158.27M)(178.79M)(105.92M)(134.37M)(85.33M)
Capital Expenditures(5.66M)(2.18M)(245K)(11K)(6.01K)
Acquisitions (Net)321K(20.44M)(13.78M)(105.97M)269.63K
Purchases of Investments(500K)(268.73M)(195.71M)(309.6M)(85.29M)
Sales of Investments218.13M183.71M277.87M656.22M148.41M
Other Investing Activities(14.91M)416K865K255K49.11K
Investing Cash Flow197.38M(107.22M)68.99M240.89M63.44M
Debt Repayment2.22M393K(3.34M)(3.39M)0
Common Stock Issued38.03M332K1.15M895K106.25K
Common Stock Repurchased(13.33M)(26.49M)(19.65M)(107.56M)(2.06M)
Dividends Paid00000
Other Financing Activities33.84M(4.07M)99.98M93.1M(4.39M)
Financing Cash Flow22.73M(29.83M)78.14M(16.96M)(6.34M)
Effect of Forex Changes(1K)00019.83K
Net Change in Cash61.83M(315.84M)41.22M89.56M(28.22M)
Free Cash Flow(163.94M)(180.97M)(106.16M)(134.38M)(85.34M)

PureTech Health plc

NASDAQ:PRTC

Intrinsic Alpha fair value

Locked

Current Price

$17.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.